← Back to Clinical Trials
Recruiting NCT07574359

NCT07574359 RUSS-AGE: Creating of a Biological Age Calculator and Study of Aging Phenotypes in the Russian Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07574359
Status Recruiting
Phase
Sponsor Pirogov Russian National Research Medical University
Condition Healthy Aging
Study Type OBSERVATIONAL
Enrollment 3,500 participants
Start Date 2023-01-12
Primary Completion 2029-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,500 participants in total. It began in 2023-01-12 with a primary completion date of 2029-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a multi-center, cross-sectional, observational study aimed at developing biological age calculators specifically for the Russian population investigating various aging phenotypes. Aging is a complex process that varies greatly between individuals, meaning that chronological age does not always reflect one's biological health status. The primary goal of this study is to identify and analyze a comprehensive set of markers (including socioeconomic factors, lifestyle, physical parameters, cognitive function, and laboratory biomarkers) that best reflect the aging process. Using this data, researchers will create a mathematical model to estimate a person's "biological age." The study plans to enroll at least 3,500 male and female volunteers aged 18 years and older from across Russia. Participants will be divided into 5-year age groups (e.g., 18-24, 25-29, up to 90+ years) to ensure broad representation. Participation involves a single visit to a clinical center. During this visit, participants will undergo: Interview and questionnaires (assessing health history, lifestyle, socioeconomic status, diet, sleep, and quality of life). Physical examination and anthropometric measurements (height, weight, blood pressure, grip strength). Functional and cognitive tests (e.g., walking speed, balance tests, memory and attention tasks tailored to age). Collection of biomaterials: blood (50 ml), urine, and stool samples for extensive laboratory analysis, including routine tests and specialized aging biomarkers. Part of the biomaterials will be biobanked for future scientific research. Instrumental examinations for a subset of participants: Depending on the center's capabilities and the study protocol, some participants may also undergo additional assessments such as densitometry (bone density scan), bioimpedance analysis (body composition), and brain MRI. The results are expected to lead to the creation of a validated biological age calculator for the Russian population. This tool could help identify targets for interventions to promote healthy aging and, in the future, potentially predict the risk of developing age-related chronic diseases.

Eligibility Criteria

Inclusion Criteria: Signing the informed consent form to participate in the study. Participant's age was 18 years or older at the time of inclusion in the study. \- Exclusion Criteria: 1. Refusal to participate in the study or to provide informed consent. 2. History or medical records indicating the presence of infectious diseases (Hepatitis C, Hepatitis B, including HBsAg carrier status, HIV infection). 3. Presence of an acute illness/condition, exacerbation of a chronic disease, or surgical intervention within the last month prior to study inclusion. 4. Lack of remission from an oncological disease or ongoing anti-tumor therapy initiated less than three years prior to study inclusion. 5. Severe cognitive or sensory impairments and mental disorders that, in the investigator's opinion, preclude adequate communication with the subject. 6. Severe forms of chronic non-communicable diseases: life-threatening cardiac arrhythmias, chronic heart failure NYHA Class III-IV, left ventricular ejection fraction \<40%, ischemic heart disease CCS Class III-IV, chronic kidney disease Stages 4-5, type 1 diabetes mellitus, type 2 diabetes mellitus with terminal stages of complications, systemic connective tissue diseases, chronic obstructive pulmonary disease with respiratory failure of Grade 1 or higher, bronchial asthma requiring glucocorticosteroid therapy, osteoarthritis Kellgren-Lawrence Grade IV, body mass index (BMI) ≥40 kg/m², as well as documented history of myocardial infarction (MI) or acute cerebrovascular accident (stroke). 7. Pregnancy or lactation (breastfeeding). 8. Any other factors that, in the investigator's opinion, may preclude the participant's inclusion in the study. Additional exclusion criteria for participants undergoing stool sample collection: 9. Use of systemic antibiotics for 3 or more days within the 3 months prior to the study start. 10. Any invasive procedures on the large intestine within the last 3 weeks prior to the study start.

Contact & Investigator

Central Contact

Liubov Machekhina, MD, PhD

✉ machehina_lv@rgnkc.ru

📞 +79037488543

Frequently Asked Questions

Who can join the NCT07574359 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07574359 currently recruiting?

Yes, NCT07574359 is actively recruiting participants. Contact the research team at machehina_lv@rgnkc.ru for enrollment information.

Where is the NCT07574359 trial being conducted?

This trial is being conducted at Moscow, Russia.

Who is sponsoring the NCT07574359 clinical trial?

NCT07574359 is sponsored by Pirogov Russian National Research Medical University. The trial plans to enroll 3,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology